Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (± 95% confidence interval) of a new user continuing donepezil at 90 days was .797 ± .103 and at 180 days was .627 ± .124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.
- Cognitive disorders/dementia
- Medication adherence